Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
11.35
+1.02 (9.87%)
At close: Oct 6, 2025, 4:00 PM EDT
11.26
-0.09 (-0.79%)
After-hours: Oct 6, 2025, 7:14 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 131 employees as of September 30, 2024. The number of employees decreased by 14 or -9.66% compared to the previous year.
Employees
131
Change (1Y)
-14
Growth (1Y)
-9.66%
Revenue / Employee
$494,702
Profits / Employee
-$702,382
Market Cap
316.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | 141 | 9 | 6.82% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENTA News
- 4 days ago - Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 5 days ago - Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 6 days ago - Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Business Wire
- 6 days ago - Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 7 days ago - Enanta Pharmaceuticals, Inc. - Special Call - Seeking Alpha
- 7 days ago - Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change - Seeking Alpha
- 7 days ago - Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Business Wire
- 10 days ago - Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Business Wire